www.Pyranosis.com - Recently-discovered information from the Sumerian records by Dr. Scott McQuate exposes secrets that have been hidden for thousands of years within the Cuneiform and even the Bible. This never-before-seen research reveals forbidden knowledge that connects human genetics with Israel, Eden and the Great Pyramid of Egypt. It is some of the most fascinating information you will ever see and challenges all previous religious dogma and scientific curriculum. Go now and discover what the world has never known. www.Pyranosis.com - Also be sure to watch his lecture at http://youtu.be/GEe7jIkn0Js
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, has announced the launch of ScienceCloud, a new SaaS-based information management and collaboration workspace. ScienceCloud advances collaborative drug discovery with a new generation of integrated applications built on a scalable, cloud-based scientific platform. With no software to manage and no hardware to maintain, ScienceCloud improves operational excellence in globally networked research, significantly reducing IT cost and effort.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65595-sciencecloud-software-by-accelrys-advances-collaborative-drug-discovery
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced its next-generation mobile strategy for the laboratory―to provide a flexible and secure mobile computing environment that effectively connects scientists, equipment and materials in today’s laboratories where an increasing number and variety of mobile devices, from smart phones to tablet computers, are in use. With over a decade of experience in pioneering paperless, mobile computing and wireless compliance capabilities in regulated laboratories, Accelrys will empower organizations to deploy purpose-built mobile applications in the lab from research to manufacturing, satisfying specific workflow requirements in accordance with Good Manufacturing Practice.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65931-accelrys-capture-drives-next-generation-mobility-in-the-laboratory
St. Jude Children’s Research Hospital, www.stjude.org, announced today the appointment of James R. Downing, M.D., as its new CEO, effective July 15, 2014. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital, which is leading the way the world understands, treats and defeats pediatric cancer and other catastrophic diseases. Downing’s primary focus immediately upon assuming the CEO office will be to oversee a new era of clinical, research and infrastructure expansion throughout the St. Jude global network. He succeeds Dr. William E. Evans, who is retiring from the position after 10 years and returning full time to his long-standing pharmacogenomics research program at St. Jude.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256651-st-jude-children-s-research-hospital-new-era-of-expansion-and-growth/
Featuring a noted cancer researcher, animal behaviorists and a 14-year-old entrepreneur who developed a new product to ease pets’ separation anxiety, Purina’s second Better With Pets Summit emphasized how technology and scientific advances are leading to a brighter future with our pets. The daylong event, Tuesday, in New York City featured 15 expert presentations on scientific, nutritional and behavioral innovations to help better understand why our lives are better with pets.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7325551-purina-better-with-pets-summit-2014/
Pure Grown Diamonds announces a scientific breakthrough with the unveiling of the first-ever, world’s largest, laboratory-cultivated brilliant white diamonds that are indistinguishable from mined diamonds, even under a microscope, yet cost 30 to 40 percent less — just in time for New Year’s Eve when millions of Americans get engaged.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7409851-pure-grown-diamonds-worlds-largest-laboratory/
Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which will be presented today at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
The study is one of four being featured at the plenary session press briefing, which highlights research that ASCO deems as having the highest scientific merit and greatest potential to affect patient care.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7532851-st-jude-cancer-research/
Subaru of America, Inc. today announced the completion of a Pet Travel Seat Pilot Study as part of its continued partnership with Center for Pet Safety (CPS), a registered 501(c)(3) non-profit research and consumer advocacy organization. Subaru and CPS have tested pet products most commonly used by pet parents when traveling. Phase one tested pet harnesses, phase two tested pet crates and carriers, and now, phase three has tested pet travel seats.
A pet travel seat is typically used in a vehicle to hold or elevate the pet, but does not offer full containment. The Pet Travel Seat Pilot Study found that while a pet travel seat may offer distraction prevention, it will likely not offer crash protection in the event of an accident, which could lead to injury of the pet and the human vehicle passengers. The quality of commonly available pet travel seats did not provide effective protection in a crash scenario.
Based on the scientific test evidence collected over the past four years, in part through its partnership with Subaru, CPS can now identify the safest travel options for most pets. For small dogs and cats, Center for Pet Safety recommends one of the 2015 Top Performing Carriers; for medium and large dogs either the 2015 Top Performing Crate - Gunner Kennels G1 Intermediate with 8' Tie Down Straps, or a Center for Pet Safety Certified Harness. To view top performing products and CPS Certified products, visit www.CenterforPetSafety.org.
To view the multimedia release go to:
http://www.multivu.com/players/English/7074158-subaru-cps-pet-travel-seat-study/
The Egyptian Ministry of Antiquities is pleased to announce the launch of an egyptian – international Project using non-invasive and non-destructive surveying techniques for the scanning of Egyptian Pyramids under the title “ScanPyramids” project.
Just because a mystery is 4500 years old doesn’t mean it can’t be solved…” This could be the motto of the exceptional scientific mission launched October 25, 2015, under the authority of the Egyptian Ministry of Antiquities, initiated, designed and coordinated by the Faculty of Engineering of Cairo and the French HIP.Institute (Heritage, Innovation and Preservation). Radiographic muons, aka cosmic particles, infrared thermography, photogrammetry, scanner and 3D reconstruction: the most innovative technologies will be used by researchers of international renown and three major universities: the Faculty of Engineering of Cairo University, Université Laval of Quebec and Nagoya University of Japan. Their goal: to probe the heart of the largest pyramids of Egypt, without drilling the slightest opening.
Four millennia after their construction, these ancient giants are far from having yielded their secrets. The first mystery concerns their construction, especially Khufu, the last of the Seven Wonders of the Ancient World still existing: it is still impossible to describe with certainty how this stone monument, the largest ever built by humans, was erected.
The “ScanPyramids” project has already been approved by the permanent committee of the Ministry of Antiquities and has obtained all necessary permissions from concerned authorities. With a base of more than 5 hectares, its original height of almost 150 meters and a mass of 5 million tons, how was it possible to construct such a wonder in only 25 years?
To view the multimedia release go to:
http://www.multivu.com/players/uk/7671551-scanpyramids-project-launch-egyptian/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
